指南与共识泌尿生殖腹部CTMRUSPET

ACR适宜性标准®:临床局限性肾细胞癌治疗后随访与主动监测的2021年更新

ACR Appropriateness Criteria® Post-Treatment Follow-up and Active Surveillance of Clinically Localized Renal Cell Carcinoma: 2021 Update.
指南 / 共识 · J Am Coll Radiol · 2022-01-01

该指南针对临床局限性肾细胞癌经根治性/部分肾切除或消融治疗后、以及活检证实或疑似局限性肾细胞癌行主动监测的无症状患者,采用RAND/UCLA适宜性方法和GRADE对影像检查进行适宜性评级,强调影像学是监测复发和疾病进展最有价值的组成部分,因多数复发和进展在无症状时被发现。

要点

  • 影像学是肾细胞癌治疗后或主动监测随访中最有价值的监测手段,多数复发和进展在无症状时被检出。
  • 制定随访方案时需理解各种影像检查在检出疾病、复发或进展方面的优势与局限。
  • 指南采用RAND/UCLA适宜性方法和GRADE对特定临床场景的影像检查进行适宜性评级,证据不足时以专家意见补充。

核心结论

  • 肾细胞癌占大多数恶性肾肿瘤,被认为是所有泌尿系统癌症中最致命的。
  • 对已治疗或未治疗的肾细胞癌患者以及疑似肾细胞癌的肿瘤患者进行随访时,影像学是监测中最有价值的组成部分,因为大多数复发和疾病进展病例是在患者无症状时被发现的。
  • 在规划随访方案时,理解各种影像检查在检出疾病、复发或进展方面的优势与局限至关重要。

研究设计与样本

  • 美国放射学会适宜性标准是由多学科专家小组每年审查的、针对特定临床情况的循证指南。
  • 指南制定和修订包括对同行评审期刊当前医学文献的广泛分析,并应用成熟方法(RAND/UCLA适宜性方法和推荐分级的评估、制定与评价即GRADE)对特定临床场景的影像和治疗程序进行适宜性评级。
  • 在证据缺乏或模棱两可的情况下,专家意见可补充现有证据以推荐影像或治疗。

诊断标准与关键数值

  • 文件涉及经根治性肾切除、部分肾切除或消融治疗的无症状肾细胞癌患者的适宜影像检查。
  • 文件还讨论了经活检证实或疑似局限性肾细胞癌、正在接受主动监测的无症状患者的适宜影像检查。

临床应用与阅片要点

  • 对已治疗或未治疗的肾细胞癌患者以及疑似肾细胞癌的肿瘤患者,影像学是监测中最有价值的组成部分。
  • 在规划随访方案时,需理解各种影像检查在检出疾病、复发或进展方面的优势与局限。

局限性

  • 在证据缺乏或模棱两可的情况下,专家意见可补充现有证据以推荐影像或治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Renal cell carcinoma (RCC) accounts for most malignant renal tumors and is considered the most lethal of all urologic cancers. For follow-up of patients with treated or untreated RCC and those with neoplasms suspected to represent RCC, radiologic imaging is the most valuable component of surveillance, as most relapses and cases of disease progression are identified when patients are asymptomatic. Understanding the strengths and limitations of the various imaging modalities for the detection of disease, recurrence, or progression is essential when planning follow-up regimens. This document addresses the appropriate imaging examinations for asymptomatic patients who have been treated for RCC with radical or partial nephrectomy or ablative therapies. It also discusses the appropriate imaging examinations for asymptomatic patients with localized biopsy-proven or suspected RCC undergoing active surveillance. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer-reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.

来源:J Am Coll Radiol,查看原文。版权归原作者所有。

引用

  1. Purysko AS, Nikolaidis P, Khatri G, et al. ACR Appropriateness Criteria® Post-Treatment Follow-up and Active Surveillance of Clinically Localized Renal Cell Carcinoma: 2021 Update. J Am Coll Radiol. 2022. PMID: 35550799. doi:10.1016/j.jacr.2022.02.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。